NCT07686575 Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
| NCT ID | NCT07686575 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhujiang Hospital |
| Condition | HNSCC |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-01-26 |
| Primary Completion | 2026-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2026-01-26 with a primary completion date of 2026-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and oropharyngeal squamous cell carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. Histopathologically diagnosed as oral squamous cell carcinoma (OSCC) or oropharyngeal squamous cell carcinoma (OPSCC) 2. Patients staged according to the AJCC criteria (8th edition) as locally advanced (Stage III/IVA oral cancer, HPV-negative oropharyngeal cancer, or Stage II/III HPV-positive oropharyngeal cancer) and assessed by the investigators as resectable. 3. Age 18 to 80 years 4. Complete blood count (CBC): White blood cell (WBC) count ≥3×10⁹/L; Platelet (PLT) count ≥75×10⁹/L; Hemoglobin (Hb) concentration ≥80g/L 5. Liver function: Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN) 6. Kidney function: Estimated glomerular filtration rate (eGFR) \> 50 mL/min 7. Patients must have adequate function of vital organs (including cardiac, pulmonary, thyroid, and other organs) and a general condition that allows tolerance of the treatment regimen of this study. 8. Sign the Informed Consent Form (ICF) Exclusion Criteria: 1. Pregnancy or lactation (for female participants) 2. A history of epilepsy or mental illness that is not effectively controlled 3. Unresolved toxicities of grade \> 2 per CTCAE criteria resulting from prior anticancer therapy 4. Other conditions deemed unsuitable for study participation by the investigators, including patients with autoimmune diseases or those at high risk of bleeding due to various causes
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07686575 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying HNSCC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07686575 currently recruiting?
Yes, NCT07686575 is actively recruiting participants. Contact the research team at lxzsurgeon@126.com for enrollment information.
Where is the NCT07686575 trial being conducted?
This trial is being conducted at Guangzhou, China, Guangzhou, China.
Who is sponsoring the NCT07686575 clinical trial?
NCT07686575 is sponsored by Zhujiang Hospital. The trial plans to enroll 20 participants.